A real world study of the efficacy and safety of belliumab in children with lupus nephritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200064053

Enrollment

Unknown

Registered

2022-09-24

Start date

2022-09-26

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lupus nephritis in children

Interventions

Belliumab treatment group:no

without Belliumab treatment group:no

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Age: 5 to 17 years old; ? Meet the criteria for the diagnosis of SLE (according to the 2019 EULAR/ACR classification criteria for SLE). The diagnostic criteria of lupus nephritis in children were referred to the "Guidance for The Verification of Diagnosis and Treatment of Lupus Nephritis (2016)" issued by Pediatrics Society of Chinese Medical Association. ? Divided into 2 groups: 1) LN standard treatment + belizumab treatment group. 2) LN standard treatment group: LN standard treatment, without the use of belizumab and other biological agents.

Exclusion criteria

Exclusion criteria: ? Age: 17 years old. ? Used biological agents in the past 1 year.

Design outcomes

Primary

Measure	Time frame
efficiency;safety;	—

Countries

China

Contacts

Public ContactQiu Li

liqiu809@126.com13708353809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026